Xellia Pharmaceuticals Tech Stack

Fermentation-based antibiotic APIs and finished injectables for global pharma supply

Pharmaceutical Manufacturing Copenhagen 1,001–5,000 employees Founded 1903 Privately Held

Xellia manufactures Active Pharmaceutical Ingredients and finished dosage forms for non-beta-lactam antibiotics—the sole European producer of several critical products. Their tech stack is firmly enterprise infrastructure (VMware, Hyper-V, NetApp, LIMS, Microsoft 365) with no cloud-native or ML adoption signals, typical for regulated manufacturing. Current hiring surge targets manufacturing and ops roles across Copenhagen and Budapest, while active projects cluster around compliance automation, serialization, and system validation—reflecting the regulatory and supply-chain pressures endemic to pharma manufacturing.

Tech Stack 13 technologies

Core StackVMware Hyper-V Windows Server Active Directory Excel LIMS Word Cloudian QNAP NetApp ONTAP Microsoft 365 PowerShell ITIL

What Xellia Pharmaceuticals Is Building

◆Challenges

Global serialization initiatives
Process standardization
Compliance of automation on production systems
Validation of new computer systems
Compliance gaps
Ensuring internal equity
External competitiveness
Gap assessments across sites
Ensuring inspection readiness
High compliance level

▲Active Projects

Global packaging transfer projects
Global serialization initiatives
New product launches
Automation compliance projects at site cph
Validation and implementation of new computer systems
Develop new sops
Conduct internal audits
Create process training materials
Global annual merit increase process
Short-term incentive plan (sti) implementation

Hiring Activity

Accelerating15 roles · 6 in 30d

Department

Manufacturing

Ops

Quality

Healthcare

Support

Seniority

Mid

Senior

Junior

Lead

Company intelligence

Find more companies like Xellia Pharmaceuticals by tech stack, pain points and active projects

Get started free

About Xellia Pharmaceuticals

Xellia supplies Active Pharmaceutical Ingredients and Finished Dosage Forms (primarily injectables) to over 500 pharmaceutical companies across 80 countries. The company operates three primary manufacturing sites—Copenhagen (Denmark), Budapest (Hungary), and Taizhou (China)—plus seven additional R&D and commercial offices. Recognized by the EU and WHO as a supplier of essential and critical medicines, Xellia serves the anti-infectives market where they hold a specialized position in fermentation-based production. The organization spans 1,001–5,000 employees and operates as a privately held firm with over 120 years of industry heritage.

HeadquartersCopenhagen

Company Size1,001–5,000 employees

Founded1903

Hiring MarketsHungary, Denmark

Frequently Asked Questions

What is Xellia Pharmaceuticals' manufacturing footprint?

Xellia operates manufacturing sites in Copenhagen (Denmark), Budapest (Hungary), and Taizhou (China), with R&D and commercial operations in seven additional countries. They serve 500+ pharmaceutical companies across 80 countries.

What does Xellia Pharmaceuticals specialize in?

Xellia specializes in fermentation-based non-beta-lactam anti-infectives, producing both Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs), primarily injectables. They are the sole European manufacturer of several products recognized as essential medicines by the EU and WHO.